Agios Pharmaceuticals Current Valuation vs. Revenue
| 8AP Stock | EUR 55.00 0.50 0.90% |
For Agios Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Agios Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Agios Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Agios Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Agios Pharmaceuticals over time as well as its relative position and ranking within its peers.
Agios |
Agios Pharmaceuticals Revenue vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Agios Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Agios Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Agios Pharmaceuticals is the top company in current valuation category among its peers. It also is the top company in revenue category among its peers totaling about 0.01 of Revenue per Current Valuation. The ratio of Current Valuation to Revenue for Agios Pharmaceuticals is roughly 71.00 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Agios Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Agios Current Valuation vs. Competition
Agios Pharmaceuticals is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 165.23 Billion. Agios Pharmaceuticals maintains roughly 1.01 Billion in current valuation contributing less than 1% to stocks in Biotechnology industry.
Agios Revenue vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Agios Pharmaceuticals |
| = | 1.01 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Agios Pharmaceuticals |
| = | 14.24 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Agios Revenue vs Competition
Agios Pharmaceuticals is the top company in revenue category among its peers. Market size based on revenue of Biotechnology industry is presently estimated at about 320.4 Billion. Agios Pharmaceuticals adds roughly 14.24 Million in revenue claiming only tiny portion of stocks in Biotechnology industry.
Agios Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Agios Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Agios Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Agios Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Agios Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. AGIOS PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 482 people.
Agios Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Agios Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Agios Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Agios Pharmaceuticals' important profitability drivers and their relationship over time.
Use Agios Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Agios Pharmaceuticals Pair Trading
Agios Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Agios Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharmaceuticals to buy it.
The correlation of Agios Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Agios Pharmaceuticals position
In addition to having Agios Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Thematic Idea Now
Insurance
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Agios Stock
To fully project Agios Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Agios Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Agios Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.